Aspirin and the prevention of cardiovascular disease in chronic kidney disease: Time to move forward?

Journal of the American College of Cardiology

Volumn 56, Issue 12, 2010, Pages 966-968

  Wali, Ravinder K ^a  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

aspirin; cardiovascular risk; chronic kidney disease; primary prevention; risk benefit analysis

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; PLACEBO;

ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LOW DRUG DOSE; NOTE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETINAL BLEEDING; SINGLE DRUG DOSE; THROMBOSIS;

EID: 77956501821     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.044     Document Type: Editorial

References (26)

1. E. Ritz, and G. Bakris World Kidney Day: hypertension and chronic kidney disease Lancet 373 2009 1157 1158
2. L.A. Stevens, and A.S. Levey Chronic kidney disease in the elderlyhow to assess risk N Engl J Med 352 2005 2122 2124
3. E.F. Elsayed, H. Tighiouart, and J. Griffith Cardiovascular disease and subsequent kidney disease Arch Intern Med 167 2007 1130 1136
4. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
5. T. Kurth, P.E. De Jong, N.R. Cook, J.E. Buring, and P.M. Ridker Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study BMJ 338 2009 b2392
6. P.A. McCullough, C.T. Jurkovitz, and P.E. Pergola Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP) Arch Intern Med 167 2007 1122 1129
7. N.S. Anavekar, J.J. McMurray, and E.J. Velazquez Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 2004 1285 1295
8. R.R. Townsend Cardiac mortality in chronic kidney disease: a clearer perspective Ann Intern Med 137 2002 615 616
9. H. Abboud, and W.L. Henrich Clinical practice Stage IV chronic kidney disease N Engl J Med 362 2010 56 65
10. R.G. Luke Chronic renal failurea vasculopathic state N Engl J Med 339 1998 841 843
11. M.W. Yerkey, S.J. Kernis, B.A. Franklin, K.R. Sandberg, and P.A. McCullough Renal dysfunction and acceleration of coronary disease Heart 90 2004 961 966
12. A.D. Lopez, and C.C. Murray The global burden of disease, 1990-2020 Nat Med 4 1998 1241 1243
13. V. Fuster, P.R. Moreno, Z.A. Fayad, R. Corti, and J.J. Badimon Atherothrombosis and high-risk plaque Part I: evolving concepts J Am Coll Cardiol 46 2005 937 954
14. Z.M. Ruggeri Platelets in atherothrombosis Nat Med 8 2002 1227 1234
15. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
16. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 396 404
17. C. Baigent, L. Blackwell, and R. Collins Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
18. T. Wolff, T. Miller, and S. Ko Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 150 2009 405 410
19. M.J. Jardine, T. Ninomiya, and V. Perkovic Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial J Am Coll Cardiol 56 2010 956 965
20. G. Eknoyan, S.J. Wacksman, H.I. Glueck, and J.J. Will Platelet function in renal failure N Engl J Med 280 1969 677 681
21. G. Remuzzi, A. Benigni, and P. Dodesini Reduced platelet thromboxane formation in uremia Evidence for a functional cyclooxygenase defect J Clin Invest 71 1983 762 768
22. H. Ogawa, M. Nakayama, and T. Morimoto Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
23. J. Belch, A. MacCuish, and I. Campbell The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease BMJ 337 2008 a1840
24. J.S. Berger, M.J. Krantz, J.M. Kittelson, and W.R. Hiatt Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials JAMA 301 2009 1909 1919
25. F.G. Fowkes, J.F. Price, and M.C. Stewart Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848
26. A. Dasgupta, S.R. Steinhubl, and D.L. Bhatt Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial) Am J Cardiol 103 2009 1359 1363